Robert B. Diasio

Q: What Schools Are Affiliated With Robert B. Diasio

Robert B. Diasio is affiliated with the following schools: University of Alabama, National University of Singapore, University of Eastern Finland, Stanford University, University of Manitoba, University of Pittsburgh, University of Southampton, University of Alabama at Birmingham

Robert B. Diasio's AcademicInfluence.com Rankings

Robert B. Diasio

Medical

#2260

World Rank

#2669

Historical Rank

Pharmacology

#232

World Rank

#272

Historical Rank

medical Degrees

Robert B. Diasio

Philosophy

#6575

World Rank

#9631

Historical Rank

Logic

#3722

World Rank

#4920

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Robert B. Diasio's Degrees

Doctorate Medicine University of Iowa
PhD Pharmacology University of Iowa

Why Is Robert B. Diasio Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert B. Diasio's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clinical Pharmacology of 5-Fluorouracil (1989) (858)
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. (2000) (850)
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. (1987) (733)
Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. (1988) (479)
Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. (1990) (460)
Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. (1993) (402)
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. (1987) (381)
Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. (2000) (363)
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population (2010) (357)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (2018) (335)
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer (2011) (306)
The continuum of care: a paradigm for the management of metastatic colorectal cancer. (2007) (247)
Biological Psychiatry (1969) (247)
Severe 5‐fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome (1991) (231)
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. (1999) (224)
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. (1987) (218)
Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. (1994) (194)
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. (2012) (182)
Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. (1996) (174)
Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. (2004) (156)
Increased Prevalence of Dihydropyrimidine Dehydrogenase Deficiency in African-Americans Compared with Caucasians (2006) (147)
Purification and characterization of dihydropyrimidine dehydrogenase from human liver. (1992) (145)
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. (2008) (144)
Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. (2001) (143)
Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. (1982) (142)
Rapid Identification of Dihydropyrimidine Dehydrogenase Deficiency by Using a Novel 2-13C-Uracil Breath Test (2004) (136)
Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. (2014) (134)
Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. (1995) (134)
Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas (2012) (131)
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). (2014) (129)
Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. (1995) (128)
Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. (2002) (124)
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. (2011) (124)
Mode of action of 5-fluorocytosine. (1978) (124)
Metabolism of pyrimidine analogues and their nucleosides. (1990) (122)
Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. (2002) (122)
5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. (1984) (121)
Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV‐infected subjects (1995) (119)
Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. (1997) (117)
Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine. (1980) (117)
Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. (1999) (115)
Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. (2002) (114)
Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. (1998) (112)
Evidence for Conversion of 5-Fluorocytosine to 5-Fluorouracil in Humans: Possible Factor in 5-Fluorocytosine Clinical Toxicity (1978) (109)
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. (2006) (105)
Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals (2005) (105)
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. (1998) (105)
Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora (1986) (103)
Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. (1994) (102)
Methylation of the DPYD Promoter: An Alternative Mechanism for Dihydropyrimidine Dehydrogenase Deficiency in Cancer Patients (2005) (97)
The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. (1998) (96)
Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. (1998) (96)
Pharmacokinetics of the fluoropyrimidines: implications for their clinical use. (1976) (94)
Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. (1997) (92)
Nomenclature for human DPYD alleles. (1998) (92)
In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. (1995) (90)
Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. (2013) (90)
Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. (1993) (90)
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. (2011) (90)
Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5‐fluorouracil chemotherapy (1995) (89)
Histone Deacetylase Inhibitors (2009) (88)
Clinical pharmacokinetics of 3′‐azido‐3′‐deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′‐amino‐3′‐deoxythymidine (1992) (87)
Role of Matrix Metalloproteinases in Colorectal Carcinogenesis (2001) (87)
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. (2006) (87)
A phosphotyrosine switch regulates organic cation transporters (2016) (85)
The Role of Pharmacogenetics and Pharmacogenomics in Cancer Chemotherapy with 5-Fluorouracil (2000) (85)
Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. (1988) (84)
Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. (2012) (81)
The Uracil Breath Test in the Assessment of Dihydropyrimidine Dehydrogenase Activity: Pharmacokinetic Relationship between Expired 13CO2 and Plasma [2-13C]Dihydrouracil (2006) (78)
A DPYD variant (Y186C) in individuals of African ancestry associated with reduced DPD enzyme activity (2013) (76)
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. (2000) (73)
Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. (2003) (73)
Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index. (1981) (70)
Clinical implications of dihydropyrimidine dehydrogenase inhibition. (1999) (70)
Antitumor Efficacy of Capecitabine and Celecoxib in Irradiated and Lead-Shielded, Contralateral Human BxPC-3 Pancreatic Cancer Xenografts: Clinical Implications of Abscopal Effects (2005) (70)
Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. (2011) (69)
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. (2005) (69)
Structural organization of the human dihydropyrimidine dehydrogenase gene. (1997) (67)
Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. (1993) (66)
microRNAs miR-27a and miR-27b Directly Regulate Liver Dihydropyrimidine Dehydrogenase Expression through Two Conserved Binding Sites (2014) (65)
DPYD*2A mutation: the most common mutation associated with DPD deficiency (2007) (60)
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy (2018) (59)
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. (2004) (57)
Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells (2001) (55)
Purification and characterization of bile acid-CoA:amino acid N-acyltransferase from human liver. (1991) (55)
Increased Expression of Thymidylate Synthetase (TS), Ubiquitin Specific Protease 10 (USP10) and Survivin is Associated with Poor Survival in Glioblastoma Multiforme (GBM) (2006) (54)
Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver. (1989) (54)
Current Status and Overview of Recent Clinical Trials (2009) (53)
The clinical case for proton beam therapy (2012) (53)
Fatty acid binding protein 3 (fabp3) is associated with insulin, lipids and cardiovascular phenotypes of the metabolic syndrome through epigenetic modifications in a northern european family population (2013) (52)
A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. (2002) (47)
Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. (2001) (47)
In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. (1995) (47)
Phase II Study of Capecitabine With Concomitant Radiotherapy for Patients With Locally Advanced Pancreatic Cancer: Up-Regulation of Thymidine Phosphorylase (2007) (47)
Predicting fluorouracil toxicity: can we finally do it? (2008) (45)
A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. (2002) (45)
Peripheral neuropathy associated with capecitabine (2004) (44)
Association Study of the let-7 miRNA-Complementary Site Variant in the 3′ Untranslated Region of the KRAS Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial) (2014) (43)
The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. (2010) (42)
Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism (2007) (42)
A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors (2010) (42)
Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties. (1993) (41)
Activation of Protein Kinase C Induces Nuclear Translocation of RFX1 and Down-regulates c-myc via an Intron 1 X Box in Undifferentiated Leukemia HL-60 Cells* (2000) (41)
Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers (2015) (41)
Capecitabine-related cardiotoxicity: recognition and management. (2008) (40)
DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS. (2006) (40)
Serum copper and zinc measurements in patients with osteogenic sarcoma (1978) (39)
Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. (1997) (38)
Distinguishing between membrane transport and intracellular metabolism of fluorodeoxyuridine in Ehrlich ascites tumor cells by application of kinetic and high performance liquid chromatographic techniques. (1979) (37)
Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer. (2019) (37)
Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. (2005) (37)
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. (2002) (36)
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients (2015) (36)
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6 q 14 and 20 q 11 (2012) (36)
The role of Sp1 and Sp3 in the constitutive DPYD gene expression. (2006) (35)
Identification of a novel percent mammographic density locus at 12q24. (2012) (35)
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? (2006) (35)
Metabolism of 5-fluorouracil to an N-cholyl-2-fluoro-beta-alanine conjugate: previously unrecognized role for bile acids in drug conjugation. (1987) (35)
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. (2002) (34)
Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells. (1985) (34)
Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. (2000) (34)
The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster (1997) (34)
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy (2014) (33)
A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. (2014) (33)
Gene‐Specific Variant Classifier (DPYD‐Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase (2018) (33)
Genetic regulation of &bgr;-ureidopropionase and its possible implication in altered uracil catabolism (2008) (33)
Effects of pH on the migration of X and Y sperm. (1971) (32)
Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy (2015) (32)
Decreased immunosuppression associated with antitumor activity of 5-deoxy-5-fluorouridine compared to 5-fluorouracil and 5-fluorouridine. (1983) (32)
Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. (1993) (30)
Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. (2007) (30)
A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. (2006) (30)
Effect of Subambient Column Temperature on Resolution of Flouorouracil Metabolites in Reversed-Phase High Performance Liquid Chromatography (1979) (30)
Alteration of the secondary structure of newly synthesized DNA from murine bone marrow cells by 5-fluorouracil. (1986) (30)
Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency (2016) (30)
HER‐2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma (2014) (30)
EGFR Somatic Mutations in Lung Tumors: Radon Exposure and Passive Smoking in Former- and Never-Smoking U.S. Women (2012) (28)
Edotecarin: a novel topoisomerase I inhibitor. (2005) (28)
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). (2016) (27)
Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers. (2016) (27)
Differential intestinal deconjugation of taurine and glycine bile acid N-acyl amidates in rats. (1992) (26)
Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis (2006) (26)
Pyrimidine and Purine Antimetabolites (2003) (26)
cis-Platinum in gynecologic cancer (1981) (25)
Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer (2005) (25)
Dihydropyrimidine dehydrogenase deficiency in an Indian population (2006) (25)
Improved measurement of thymidylate synthetase activity by a modified tritium-release assay. (1982) (24)
A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients (2004) (24)
Rapid determination of serum 5-fluorocytosine levels by high-performance liquid chromatography (1978) (23)
The effect of 5-fluorouracil on DNA chain elongation in intact bone marrow cells. (1985) (23)
Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formation. (1985) (23)
Advances in Chemotherapy of AIDS (1990) (22)
Oral Levonantradol in the Treatment of Chemotherapy‐Induced Emesis: Preliminary Observations (1981) (22)
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. (2006) (21)
Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy. (2007) (21)
Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression. (2007) (21)
Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase (2006) (21)
An evolving role for oral fluoropyrimidine drugs. (2002) (18)
Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma (2013) (18)
cis-Platinum in gynecologic cancer. III. Toxicity. (1981) (18)
Circadian variation of fluoropyrimidine catabolic enzymes in rat liver: possible relevance to 5-fluorodeoxyuridine chemotherapy. (1991) (18)
cis-Platinum in gynecologic cancer. II. Squamous cell carcinoma of the cervix. (1981) (17)
A comparative study of bile acid CoA:amino acid:N-acyltransferase (BAT) from four mammalian species. (1991) (17)
Double‐Blind Multiple‐Dose Crossover Study of the Antiemetic Effect of Intramuscular Levonantradol Compared to Prochlorperazine (1984) (17)
Biochemical Basis for Circadian‐Dependent Metabolism of Fluoropyrimidines a (1991) (17)
Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter. (2016) (17)
cDNA cloning of bovine liver dihydropyrimidine dehydrogenase. (1996) (16)
Identification of bile acid coenzyme A synthetase in rat kidney. (1993) (16)
Radioassay of bile acid coenzyme A:glycine/taurine: N-acyltransferase using an n-butanol solvent extraction procedure. (1989) (16)
Identification of bile acid-CoA: amino acid N-acyltransferase in rat kidney. (1991) (16)
E1A‐F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase‐2 and matrix metalloproteinase‐7 (2005) (15)
N-chenodeoxycholyl-2-fluoro-beta-alanine: a biliary metabolite of 5-fluorouracil in humans. (1988) (15)
Genetic Testing in Cancer Therapeutics (2006) (15)
HER2 expression/amplification: Frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). (2011) (14)
Oral DPD-inhibitory fluoropyrimidine drugs. (2000) (14)
Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy. (1991) (14)
Principles of Drug Therapy (2012) (14)
EFFECT OF ALTITUDE (HYPOXIA) ON CORONARY ARTERY SIZE IN THE WHITE RAT. (1965) (14)
Disposition and metabolism of 2-fluoro-beta-alanine conjugates of bile acids following secretion into bile. (1991) (14)
Improving Fluorouracil Chemotherapy with Novel Orally Administered Fluoropyrimidines (2012) (13)
A mathematical model of the kinetics of 5-fluorouracil and its catabolites in freshly isolated rat hepatocytes. (1984) (13)
Formation of conjugates of 2-fluoro-beta-alanine and bile acids during the metabolism of 5-fluorouracil and 5-fluoro-2-deoxyuridine in the isolated perfused rat liver. (1988) (13)
Pharmacology of therapeutic oligonucleotides. (1997) (13)
Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer (2003) (13)
13C-5-FU breath test current status and future directions: a comprehensive review (2009) (13)
Evidence from rat hepatocytes of an unrecognized pathway of 5-fluorouracil metabolism with the formation of a glucuronide derivative. (1985) (13)
Capecitabine induces rapid, sustained response in two patients with extensive oral verrucous carcinoma. (2003) (12)
Prognostic and predictive significance of 5-fluorouracil metabolic enzymes in colorectal cancer. (2006) (12)
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor (2016) (12)
Perspectives in the treatment of colorectal cancer. (2004) (12)
Bile acid conjugation pattern in the isolated perfused rat liver during infusion of an amino acid formulation. (1991) (11)
Peripheral neuropathy exacerbation associated with topical 5-fluorouracil (2006) (11)
A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors (2010) (11)
Pharmacologic study of oral ftorafur: Potential for improved oral delivery of 5-fluorouracil (1979) (10)
T4 extension alone is more predictive of better survival than a tumour size >7 cm for resected T4N0–1M0 non-small-cell lung cancer† (2018) (10)
Is It Finally Time for a Personalized Medicine Approach for Fluorouracil-Based Therapies? (2016) (10)
Circadian rhythm of rat spleen cytoplasmic thymidine kinase. (1993) (10)
Clinical and pharmacological studies of interferon and chemotherapy in gastrointestinal and breast cancer. (1993) (10)
Determination of dihydropyrimidine dehydrogenase (DPD) in fibroblasts of a DPD deficient pediatric patient and family members using a polyclonal antibody to human DPD. (1994) (10)
The Y chromosome in sperm of an XYY male. (1970) (10)
Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival (2009) (10)
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). (2019) (10)
Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? (2007) (9)
Hypokalemia secondary to capecitabine: a hidden toxicity? (2007) (9)
Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator. (1998) (9)
Pharmacogenomic‐Guided Therapy in Colorectal Cancer (2021) (8)
Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity (2021) (8)
A mathematical model of the kinetics and tissue distribution of 2-fluoro-beta-alanine, the major catabolite of 5-fluorouracil. (1993) (8)
2-Fluoro-beta-alanine, a previously unrecognized substrate for bile acid coenzyme A:amino acid:N-acyltransferase from human liver. (1990) (8)
The role of dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (dthdPase) in the circadian variation of plasma drug levels of 5-fluorouracil (FUra) and 5-fluorodeoxyuridine (FdUrd) following infusion of FUra or FdUrd (1990) (8)
Methylation of the Human Pendrin Promoter (2011) (8)
Severe Capecitabine Toxicity Associated With a Rare DPYD Variant Identified Through Whole-Genome Sequencing. (2020) (7)
Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer (2012) (7)
Adjuvant chemotherapy for adenocarcinoma of the lung--is the standard of care ready for change? (2004) (7)
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? (2007) (7)
Raltitrexed (Tomudex®): An Alternative Choice in Patients Intolerant to 5-Fluorouracil (2002) (7)
Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro. (2002) (7)
Current status of oral chemotherapy for colorectal cancer. (2001) (7)
Biological properties of the 2-fluoro-beta-alanine conjugates of cholic acid and chenodeoxycholic acid in the isolated perfused rat liver. (1990) (6)
Drug metabolism and pancreatic cancer (2016) (6)
Simultaneous detection of variable number tandem repeats, single nucleotide polymorphisms, and allelic imbalance in the thymidylate synthase gene enhancer region using denaturing high-performance liquid chromatography. (2004) (6)
5'-Deoxy-5-fluorouridine: Cellular metabolism of a new fluoropyrimidine with antineoplastic activity (1979) (6)
A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). (2013) (5)
26 Pharmacological Agents That Target DNA Replication (2006) (5)
Fluoropyrimidine catabolism. (1995) (5)
Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor? (2008) (5)
Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications (2021) (5)
Evidence for increased incidence of dihydropyrimidine dehydrogenase (DPD) deficiency in African Americans compared to Caucasians (2005) (5)
ADAM-17: A Target to Increase Chemotherapeutic Efficacy in Colorectal Cancer? (2010) (5)
Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147. (2013) (5)
Correlation of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) expression in primary and metastatic sites with response to capecitabine plus irinotecan in patients with colorectal cancer. (2004) (5)
A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies (2020) (5)
Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance (2021) (5)
Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility. (2014) (5)
FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity (2019) (4)
Predictive Biomarkers and Personalized Medicine Association Study of the let-7 miRNA-Complementary Site Variant in the 3 0 Untranslated Region of the KRAS Gene in Stage III Colon Cancer ( NCCTG N 0147 Clinical Trial ) (2014) (4)
Dose modification for safe treatment of a compound complex heterozygous DPYD variant carrier with 5-fluorouracil. (2018) (4)
A phase I study of capecitabine and concurrent radiotherapy (RT) for patients with newly diagnosed glioblastoma multiforme (GBM). (2004) (4)
Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy (2022) (4)
Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice (2020) (3)
Biomarkers of Fluorouracil Toxicity: Insight From the PETACC-8 Trial. (2016) (3)
Association of Pharmacogenetics With Adverse Events of Fluorouracil/Capecitabine in Patients With Cancer. (2021) (3)
The 2-13C-5-fluorouracil breath test (FUBT) as a novel, rapid method for assessment of dihydropyrimidine dehydrogenase (DPD) activity in cancer patients: Initial characterization and comparison to the 2-13C-uracil breath test (UraBT) (2007) (3)
Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades. (2018) (3)
HER2 testing in esophageal adenocarcinoma (EAC) using parallel tissue-based methods. (2013) (3)
Adenocarcinoma of the pancreas associated with hypoglycemia. Case report and review of the literature (1979) (3)
Fluoropyrimidines as Radiation Sensitizers (2003) (3)
Characterization of 5'-deoxy-5-fluorouridine induced inhibition of tumor cell growth in vitro (1981) (3)
Can eniluracil improve 5-fluorouracil therapy? (2002) (3)
5-fluorocytosine susceptibility of pathogenic fungi in the presence of allopurinol: potential for improving the therapeutic index of 5-fluorocytosine (1983) (3)
Rapid simultaneous analysis of fluoropyrimidine metabolite pools by a high performance liquid chromatographic-isotopic method (1978) (2)
Up-regulation of thymidine phosphorylase (TP) by radiotherapy (RT): a phase I study of capecitabine (CAP) with concurrent RT for pts with locally advanced (LA) pancreatic cancer (Pan Ca). (2004) (2)
High-performance liquid chromatographic determination of 9-(3-pyridylmethyl)-9-deazaguanine (BCX-34) in biological fluids. (1997) (2)
Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147). (2012) (2)
Supplementary Figures 1-18 (2010) (2)
Hand-foot syndrome (HFS) in patients treated with capecitabine (CAP) and the role of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD). (2006) (2)
Pharmacological and Therapeutics agents that Target DNA Replication (2005) (2)
Novel chemotherapeutic agents in early clinical development. (1990) (2)
Differential effect of allopurinol (hpp) on incorporation of 5-fluorouracil (fu) into rna of tumor and host cells isolated from cf1 mice bearing ehrlich ascites tumor (et). Abstr. (1981) (2)
Dose dependent inhibition of uridine phosphorylase (UP) by eniluracil (EU): Was the clinical inferiority of the EU/5-fluorouracil (5-FU) phase III trials due to an unrecognized inhibition of 5-FU anabolism? (2006) (2)
Dual role of serine hydroxymethyltransferase in the synergy of fluorouracil and leucovorin: effects of L-serine and glycine on H4PteGlu/5,10-CH2-H4PteGlu ratios; and H4PteGlu-catalyzed release of fluoride ion from alpha-fluoro-beta alanine. (1990) (2)
A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. (2009) (2)
Up-regulation of thymidine phosphorylase (TP) by radiotherapy (RT): a phase I study of capecitabine (CAP) with concurrent RT for pts with locally advanced (LA) pancreatic cancer (Pan Ca) (2004) (2)
cis-Platinum in gynecologic cancer. I. Epithelial ovarian cancer. (1981) (2)
DNA repair following incorporation of 5-fluorouracil into DNA of mouse bone marrow cells (1988) (2)
Alternative schedules with irinotecan. (2003) (2)
Mutations at codon 974 of the DPYD gene are a rare event. (1997) (2)
Correction: Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients (2015) (1)
Current Leading Cause of Death in the World: Cancer versus Cardiovascular Disease (2019) (1)
Recent advances in cancer chemotherapy (1981) (1)
Genome-wide association study identifies variants at 16 p 13 associated with survival in multiple myeloma patients (2015) (1)
Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer. (2006) (1)
Pharmacogenomics and the role of genomics in cancer therapeutics (2018) (1)
Abstract 2198: Possible circadian modulation of dihydropyrimidine dehydrogenase by mir-27a and mir-27b. (2013) (1)
Bone marrow (BM) toxicity secondary to fluoropyrimidine (FP) drugs; Incorporation into RNA as the major determinant of BM toxicity (1982) (1)
Genotypic characterization of dihydropyrimidinase andβ-ureidopropionase in an African American and Caucasian population: New potential pharmacogenetic markers for 5-fluorouracil toxicity in the African American population (2007) (1)
HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) to predict toxicity in stage III colon cancer (CC) patients (pts) (NCCTG Alliance N0147). (2015) (1)
Clinical Implications of Dihydropyrimidine Dehydrogenase on 5-Fluorouracil Pharmacology (2002) (1)
Evidencefrom Rat Hepatocytesof an UnrecognizedPathwayof 5-Fluorouracil Metabolismwith the Formationof a GlucuronideDerivative1 (1985) (1)
Dihydropyrimidine dehydrogenase and resistance to 5-fluorouracil. (1999) (1)
Erratum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients (Nature Communications (2015) 6 (7539) DOI: 10.1038/ncomms8539) (2015) (1)
Rate of incorporation of fluorouracil into RNA as the basis for differential fluoropyrimidine biological activity (1981) (1)
Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: Experience of 4 years. (2006) (1)
Human Respiration: A Programmed Course (1969) (1)
Molecular basis of altered uracil catabolism in individuals with 5-FU toxicity and normal DPD enzyme activity. (2006) (1)
DPYD Testing: Time to Put Patient Safety First. (2023) (1)
Levonantradol, a synthetic cannabinoid with potential usefulness as an antiemetic in chemotherapy-induced emesis (1981) (1)
Validation of a novel [2-13C]-uracil breath test (UraBT) to detect dihydropyrimidine dehydrogenase (DPD) deficiency by LC-MS-MS analysis of [2-13C]-uracil (URA) and [2-13C]-dihydrouracil (DHU) plasma levels. (2004) (1)
The clinical case for proton beam therapy (2012) (1)
5'-Deoxy-5-fluorouridine: A model substrate for the study of pyrimidine nucleoside transport (1982) (1)
Host interactions in the effects of 5-fluorouracil on Ehrlich ascites tumor cells. (1982) (1)
Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase (TP) and its correlation with survival (2007) (1)
Reversible 5‐fluorouracil‐associated encephalopathy in a dihydropyrimidine dehydrogenase (DPD) deficient patient (1996) (1)
Imaging , Diagnosis , Prognosis Association of HER 2 / ErbB 2 Expression and Gene Ampli fi cation with Pathologic Features and Prognosis in Esophageal Adenocarcinomas (2012) (1)
Erratum: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects (Clinical Pharmacology and Therapeutics (1995) 58 (44-53) DOI: 10.1016/0009-9236(95)90071-3) (2011) (0)
The Y-chromosome-bearing sperm: a re-examination of the sex ratio in man, and new implications on the heredity of the XYY syndrome (1971) (0)
Cancer Biology and Signal Transduction microRNAs miR-27 a and miR-27 b Directly Regulate Liver Dihydropyrimidine Dehydrogenase Expression through Two Conserved Binding Sites (2014) (0)
Biochemical basis for the superior therapeutic index of 5'-deoxy-5-fluorouridine (1981) (0)
Silencing of SHP1 Is Frequent in Phospho-STAT3 Positive Diffuse Large Cell Lymphoma and This Silencing Is Independent of Methylation of Cpg Islands, (2011) (0)
Co-expression of cyclooxygenase-2 (COX-2) and matrixmetalloproteinase (MMP)-2,-7 and-9 in human colorectal cancer (2001) (0)
Orcadian Variation of 5-FIuorouracil Catabolism in Isolated Perfused Rat Liver 1 (2006) (0)
Adverse prognostic impact of heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma (EAC). (2012) (0)
Pharmacological evaluation of antineoplastic agents (1984) (0)
Radiation modulates fluoropyrimidine metabolism in human glioblastoma cells through cytokine-mediated induction of thymidine phosphorylase expression (2002) (0)
Abstract 5487: Functional analysis of rare dihydropyrimidine dehydrogenase variants relevant to 5-fluorouracil toxicity (2015) (0)
Prognostication of Long-Term Survival in Resected Esophageal Adenocarcinoma (EAC): 20 (2010) (0)
Overview of Cancer Pharmacogenomics (2008) (0)
FUSAFE abstract on MIR27A/DPYD genotyping (2020) (0)
Abstract LB-195: The intronic DPYD variant rs75017182 correlates with a modest reduction in DPD enzyme activity (2016) (0)
Advances in Brief Capecitabine Induces Rapid , Sustained Response in Two Patients with Extensive Oral Verrucous Carcinoma 1 (2003) (0)
Nucleoside transport in Ehrlich ascites tumor cells: The critical distinction between transport and metabolism of fluorodeoxyuridine (1978) (0)
404MO Clinical relevance of MIR27A rs895819 polymorphism and its interaction with DPYD variants for predicting grade 4-5 fluoropyrimidine (FP) toxicity (tox) in the FUSAFE individual patient data meta-analysis (IPD-MA) (2020) (0)
intestinal deconjugation of taurine bile acid N-acyl amidates in rats (1992) (0)
Abstract 5805: Novel approach to thymidylate synthase genotype determination and utility as a biomarker of severe toxicity to 5-FU chemotherapy (2022) (0)
Intracellular pharmacology of 5'-deoxy-5-fluorouridine (5' -dFUR) compared with 5-fluorouracil (FU), 5-fluorouridine (FUR), and 5-fluoro-2'-deoxyuridine (FUdR) (1981) (0)
Genomic Guided Therapy in Cancer Patients (2013) (0)
Phase II and pharmacogenetic study of docetaxel (D) and capecitabine (C) in chemonaive non-small cell lung cancer (NSCLC) patients (pts) (2008) (0)
4–35 CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment (2006) (0)
Abstract 3894: DPYD-Varifier, a computational model to identify 5-FU toxicity-associated DPYD variants (2018) (0)
LBOVI‐B‐2 (2006) (0)
5-Fluorouracil formation from 5-fluorocytosine in man: a possible factor in the clinical toxicity of 5-fluorocytosine (1978) (0)
Fatty acid binding protein 3 (fabp3) is associated with insulin, lipids and cardiovascular phenotypes of the metabolic syndrome through epigenetic modifications in a northern european family population (2013) (0)
Effect of column temperature on resolution in reverse phase high performance liquid chromatography; use of subambient temperature to improve the resolution of a mixture of fluoropyrimidine compounds (1978) (0)
Prognosticationofpancreatic adenocarcinomabyexpression ofthymidinephosphorylase/ dihydropyrimidine dehydrogenaseratioandits correlationwithsurvival (2009) (0)
Abstracts of oral presentations (2005) (0)
Metabolism of 5 fluorouracil and 5 fluorodeoxyuridine in the isolated perfused rat liver identification of novel conjugates of 2 fluoro beta alanine and bile acids (1987) (0)
Molecular characterization of the dihydropyrimidine dehydrogenase gene (1997) (0)
Abstract 5420: DPYD enhancer variant confers increased risk of severe toxicity in 5-FU chemotherapy (2022) (0)
Post-recurrence survival in patients with previously resected esophageal adenocarcinoma (EAC). (2012) (0)
Incorporation of fluoropyrimidine (FP) drugs into RNA as the major determinant of cytotoxicity in host and tumor cells (1982) (0)
Genotyping of Caucasian individuals in the dihydropyrimidine dehydrogenase gene (2005) (0)
Contributors (2012) (0)
Abstract 5451: High-throughput detection of dihydropyrimidine dehydrogenase gene (DPYD) variants using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) (2011) (0)
Abstract 911: Targeting the mutant KRAS/BRAF-induced enhancer as an approach to overcome resistance to 5-fluorouracil-based chemotherapy in colorectal cancer (2018) (0)
A Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics (1998) (0)
Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine. (2023) (0)
HER2 status in primary tumors and metastatic regional lymph nodes in patients with esophageal adenocarcinoma (EAC). (2013) (0)
Mechanism of fluoropyrimidine (FP) toxicity in Ehrlich ascites tumor cells (EA); Inhibition of thymidylate synthetase activity (TSA) vs. incorporation into RNA at equitoxic doses of four FP drugs (1982) (0)
Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes. (2012) (0)
Abstract 4404: Post-transcriptional regulation of dihydropyrimidine dehydrogenase (DPD) by the microRNAs mir27a and mir27b (2011) (0)
Association of body mass index (BMI) with smoking and prognosis in 721 patients with esophagogastric adenocarcinoma. (2011) (0)
Abstract B49: Histone H3K27 tri-methylation regulates DPYD expression and cellular sensitivity of 5-fluorouracil (2016) (0)
Abstract 3893: Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity (2018) (0)
Elucidating the mechanisms responsible for the previous failure of phase III clinical trials with eniluracil (EU) and development of a novel scheduling approach to optimize the efficacy of EU/5-fluorouracil (5-FU) combination therapy (2007) (0)
Acknowledgement of reviewers 2020 (2021) (0)
Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient (2016) (0)
Cancer trends: surgical adjuvant chemotherapy for operable breast cancer. (1980) (0)
Comparison of HER2 gene amplification (AMP) in primary esophageal and gastroesophageal junction adenocarcinomas (EAC) and their metastatic regional lymph nodes (MLNs). (2015) (0)
P-211 Phase II study of docetaxel in combination with capecitabine in patients with previously treated non-small cell lung cancer (NSCLC) (2003) (0)
Selecting regimens in advanced colon cancer. (2004) (0)
The characteristics of 5'-deoxy-5-fluorouridine uptake in Ehrlich ascites tumor cells in vitro (1981) (0)
Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil. (2016) (0)
Genetics and Cancer (1977) (0)
PD-021 Tissue microarray for protein profiling in non-small cell lungcancer (NSCLC): Discovery and validation of novel biomarkers for prediction of recurrence and treatment response (2005) (0)
Analysis of 3H fluorouracil (FUra) catabolism by HPLC in freshly isolated rat hepatocytes (1982) (0)
Association study of the let-7 microRNA-binding site polymorphism in 3'-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147. (2012) (0)
Demonstration and characterization of DNA repair in bone marrow cells following fluorouracil (FU) incubation (1985) (0)
Decreased immunosuppression associated with anti-tumor activity of 5'-dFUrd compared to 5-FUra and 5-FUrd (1983) (0)
Abstract 4069: Trimethylation and acetylation of Histone H3K27 modulates 5-fluorouracil response by regulating DPYD expression (2017) (0)
The Isolated Hepatocyte and Isolated Perfused Liver as Models for Studying Drug- and Chemical-Induced Hepatotoxicity (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert B. Diasio?

Robert B. Diasio is affiliated with the following schools:

Robert B. Diasio's Academic­Influence.com Rankings

Robert B. Diasio's Degrees

Why Is Robert B. Diasio Influential?

Robert B. Diasio's Published Works

Published Works

What Schools Are Affiliated With Robert B. Diasio?

Robert B. Diasio's AcademicInfluence.com Rankings